Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells

Experimental Cell Research

Volumn 316, Issue 19, 2010, Pages 3150-3160

  Gertych, Arkadiusz ^a   Farkas, Daniel L ^a   Tajbakhsh, Jian ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

3 D image analysis; 5 azacytidine; DNA methylation; Epigenetic drug screening; Heterochromatin reorganization; Zebularine

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; 5 METHYLCYTOSINE; AZACITIDINE; ZEBULARINE; ANTINEOPLASTIC AGENT; CYTIDINE; CYTOSINE; DNA; INDOLE DERIVATIVE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DENSITY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; HETEROCHROMATIN; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE PROCESSING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROSTATE CANCER; THREE DIMENSIONAL IMAGING; ANALOGS AND DERIVATIVES; CHEMISTRY; CONFORMATION; DRUG EFFECTS; FLUORESCENCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; PROCEDURES; TUMOR CELL LINE;

MAMMALIA;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CELL NUCLEUS; CYTIDINE; CYTOSINE; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; NEOPLASMS; NUCLEIC ACID CONFORMATION;

EID: 77958152747     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.08.013     Document Type: Article

References (34)

1. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
2. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
3. Gal-Yam E.N., Saito Y., Egger G., Jones P.A. Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 2008, 59:267-280.
4. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 2000, 249:135-164.
5. Balch C., Yan P., Craft T., Young S., Skalnik D.G., Huang T.H., Nephew K.P. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 2005, 4:1505-1514.
6. Marquez V.E., Kelley J.A., Agbaria R., Ben-Kasus T., Cheng J.C., Yoo C.B., Jones P.A. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. NY Acad. Sci. 2005, 1058:246-254.
7. de Capoa A., Di Leandro M., Grappelli C., Menendez F., Poggesi I., Giancotti P., Marotta M.R., Spano A., Rocchi M., Archidiacono N., Niveleau A. Computer-assisted analysis of methylation status of individual interphase nuclei in human cultured cells. Cytometry 1998, 31:85-92.
8. Gertych A., Wawrowsky K.A., Lindsley E., Vishnevsky E., Farkas D.L., Tajbakhsh J. Automated quantification of DNA demethylation effects in cells via 3D mapping of nuclear signatures and population homogeneity assessment. Cytom. A 2009, 75:569-583.
9. Gilbert N., Thomson I., Boyle S., Allan J., Ramsahoye B., Bickmore W.A. DNA methylation affects nuclear organization, histone modifications, and linker histone binding but not chromatin compaction. J. Cell Biol. 2007, 177:401-411.
10. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol. Ther. 1995, 65:19-46.
11. Santos A.P., Abranches R., Stoger E., Beven A., Viegas W., Shaw P.J. The architecture of interphase chromosomes and gene positioning are altered by changes in DNA methylation and histone acetylation. J. Cell Sci. 2002, 115:4597-4605.
12. Tajbakhsh J., Wawrowsky K.A., Gertych A., Bar-Nur O., Vishnevsky E., Lindsley E.H., Farkas D.L. Characterization of tumor cells and stem cells by differential nuclear methylation imaging. Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues SPIE, San Jose 2008, vol. 6859:68590F. D.L. Farkas, D.V. Nicolau, R.C. Leif (Eds.).
13. Lewis J., Bird A. DNA methylation and chromatin structure. FEBS Lett. 1991, 285:155-159.
14. Lang P., Yeow K., Nichols A., Scheer A. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 2006, 5:343-356.
15. Cheng J.C., Matsen C.B., Gonzales F.A., Ye W., Greer S., Marquez V.E., Jones P.A., Selker E.U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 2003, 95:399-409.
16. de Capoa A., Menendez F., Poggesi I., Giancotti P., Grappelli C., Marotta M.R., Di Leandro M., Reynaud C., Niveleau A. Cytological evidence for 5-azacytidine-induced demethylation of the heterochromatic regions of human chromosomes. Chromosome Res. 1996, 4:271-276.
17. Dote H., Cerna D., Burgan W.E., Carter D.J., Cerra M.A., Hollingshead M.G., Camphausen K., Tofilon P.J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin. Cancer Res. 2005, 11:4571-4579.
18. Stresemann C., Brueckner B., Musch T., Stopper H., Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006, 66:2794-2800.
19. Scheuermann M.O., Tajbakhsh J., Kurz A., Saracoglu K., Eils R., Lichter P. Topology of genes and nontranscribed sequences in human interphase nuclei. Exp. Cell Res. 2004, 301:266-279.
20. Tajbakhsh J., Luz H., Bornfleth H., Lampel S., Cremer C., Lichter P. Spatial distribution of GC- and AT-rich DNA sequences within human chromosome territories. Exp. Cell Res. 2000, 255:229-237.
21. Collins T.J. ImageJ for microscopy. Biotechniques 2007, 43:25-30.
22. Bushberg J., Seibert J., L.J.E., Boone J. The Essential Physics of Medical Imaging 2001, Lippincott Williams & Wilkins, Philadelphia.
23. Haralick R.M. Mathematical morphology: theory and applications 1996, Oxford University Press, New York.
24. Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6:151-158.
25. Yoo C.B., Cheng J.C., Jones P.A. Zebularine: a new drug for epigenetic therapy. Biochem. Soc. Trans. 2004, 32:910-912.
26. Shiels C., Adams N.M., Islam S.A., Stephens D.A., Freemont P.S. Quantitative analysis of cell nucleus organisation. PLoS Comput. Biol. 2007, 3:e138.
27. Bolzer A., Kreth G., Solovei I., Koehler D., Saracoglu K., Fauth C., Muller S., Eils R., Cremer C., Speicher M.R., Cremer T. Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. PLoS Biol. 2005, 3:e157.
28. Visser A.E., Aten J.A. Chromosomes as well as chromosomal subdomains constitute distinct units in interphase nuclei. J. Cell Sci. 1999, 112(Pt 19):3353-3360.
29. Doudkine A., Macaulay C., Poulin N., Palcic B. Nuclear texture measurements in image cytometry. Pathologica 1995, 87:286-299.
30. Huisman A., Ploeger L.S., Dullens H.F., Poulin N., Grizzle W.E., van Diest P.J. Development of 3D chromatin texture analysis using confocal laser scanning microscopy. Cell. Oncol. 2005, 27:335-345.
31. Csoka A.B., Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med. Hypotheses 2009, 73:770-780.
32. Ammerpohl O., Martin-Subero J.I., Richter J., Vater I., Siebert R. Hunting for the 5th base: techniques for analyzing DNA methylation. Biochim. Biophys. Acta 2009, 1790:847-862.
33. Lister R., Ecker J.R. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res. 2009, 19:959-966.
34. Smith Z.D., Gu H., Bock C., Gnirke A., Meissner A. High-throughput bisulfite sequencing in mammalian genomes. Methods 2009, 48:226-232.